|
1
|
Yang M and Pyo MY: Molecular epidemiology
of lung cancer in female passive smokers. J Environ Sci Health C
Environ Carcinog Ecotoxicol Rev. 23:75–97. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stabile LP, Davis AL, Gubish CT, et al:
Human non-small cell lung tumors and cells derived from normal lung
express both estrogen receptor alpha and beta and show biological
responses to estrogen. Cancer Res. 62:2141–2150. 2002.PubMed/NCBI
|
|
3
|
Kuiper GG, Enmark E, Pelto-Huikko M,
Nilsson S and Gustafsson JA: Cloning of a novel receptor expressed
in rat prostate and ovary. Proc Natl Acad Sci USA. 93:5925–5930.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clarke CL and Sutherland RL: Progestin
regulation of cellular proliferation. Endocr Rev. 11:266–301. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee WS, Harder JA, Yoshizumi M, Lee ME and
Haber E: Progesterone inhibits arterial smooth muscle cell
proliferation. Nat Med. 3:1005–1008. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Groshong SD, Owen GI, Grimison B, et al:
Biphasic regulation of breast cancer cell growth by progesterone:
role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1).
Mol Endocrinol. 11:1593–1607. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Musgrove EA, Hunter LJ, Lee CS, Swarbrick
A, Hui R and Sutherland RL: Cyclin D1 overexpression induces
progestin resistance in T-47D breast cancer cells despite p27(Kip1)
association with cyclin E-Cdk2. J Biol Chem. 276:47675–47683. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Santen RJ, Manni A, Harvey H and Redmond
C: Endocrine treatment of breast cancer in women. Endocr Rev.
11:221–265. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thigpen JT, Brady MF, Alvarez RD, et al:
Oral medroxyprogesterone acetate in the treatment of advanced or
recurrent endometrial carcinoma: a dose-response study by the
Gynecologic Oncology Group. J Clin Oncol. 17:1736–1744.
1999.PubMed/NCBI
|
|
10
|
Lee YT: Better prognosis of many cancers
in female: a phenomenon not explained by study of steroid
receptors. J Surg Oncol. 25:255–262. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Su JM, Hsu HK, Chang H, et al: Expression
of estrogen and progesterone receptors in non-small-cell lung
cancer: immunohistochemical study. Anticancer Res. 16:3803–3806.
1996.PubMed/NCBI
|
|
12
|
Check JH, Sansoucie L, Chern J and Dix E:
Mifepristone treatment improves length and quality of survival of
mice with spontaneous lung cancer. Anticancer Res. 30:119–122.
2010.PubMed/NCBI
|
|
13
|
Marquez-Garban DC, Mah V, Alavi M, et al:
Progesterone and estrogen receptor expression and activity in human
non-small cell lung cancer. Steroids. 76:910–920. 2011.PubMed/NCBI
|
|
14
|
Tiutiunova AM, Chirvina ED, Mironenko TV,
Kartashov SZ and Luntovskaia VA: Hormonal balance in women with
lung cancer and its changes after combined treatment. Vopr Onkol.
32:26–30. 1986.(In Russian).
|
|
15
|
Zhu Y, Rice CD, Pang Y, Pace M and Thomas
P: Cloning, expression, and characterization of a membrane
progestin receptor and evidence it is an intermediary in meiotic
maturation of fish oocytes. Proc Natl Acad Sci USA. 100:2231–2236.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu Y, Bond J and Thomas P:
Identification, classification, and partial characterization of
genes in humans and other vertebrates homologous to a fish membrane
progestin receptor. Proc Natl Acad Sci USA. 100:2237–2242. 2003.
View Article : Google Scholar
|
|
17
|
Thomas P: Characteristics of membrane
progestin receptor alpha (mPRalpha) and progesterone membrane
receptor component 1 (PGMRC1) and their roles in mediating rapid
progestin actions. Front Neuroendocrinol. 29:292–312. 2008.
View Article : Google Scholar
|
|
18
|
Zuo L, Li W and You S: Progesterone
reverses the mesenchymal phenotypes of basal phenotype breast
cancer cells via a membrane progesterone receptor mediated pathway.
Breast Cancer Res. 12:R342010. View
Article : Google Scholar
|
|
19
|
Dosiou C, Hamilton AE, Pang Y, et al:
Expression of membrane progesterone receptors on human T
lymphocytes and Jurkat cells and activation of G-proteins by
progesterone. J Endocrinol. 196:67–77. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ciavatta VT, Kim M, Wong P, et al: Retinal
expression of Fgf2 in RCS rats with subretinal microphotodiode
array. Invest Ophthalmol Vis Sci. 50:4523–4530. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dhanesuan N, Sharp JA, Blick T, Price JT
and Thompson EW: Doxycycline-inducible expression of
SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells
results in growth inhibition. Breast Cancer Res Treat. 75:73–85.
2002. View Article : Google Scholar
|
|
22
|
Desai B, Ma T and Chellaiah MA:
Invadopodia and matrix degradation, a new property of prostate
cancer cells during migration and invasion. J Biol Chem.
283:13856–13866. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Beattie CW, Hansen NW and Thomas PA:
Steroid receptors in human lung cancer. Cancer Res. 45:4206–4214.
1985.PubMed/NCBI
|
|
24
|
Wu CT, Chang YL, Shih JY and Lee YC: The
significance of estrogen receptor beta in 301 surgically treated
non-small cell lung cancers. J Thorac Cardiovasc Surg. 130:979–986.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fasco MJ, Hurteau GJ and Spivack SD:
Gender-dependent expression of alpha and beta estrogen receptors in
human nontumor and tumor lung tissue. Mol Cell Endocrinol.
188:125–140. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kaiser U, Hofmann J, Schilli M, et al:
Steroid-hormone receptors in cell lines and tumor biopsies of human
lung cancer. Int J Cancer. 67:357–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thomas P, Pang Y, Dong J, et al: Steroid
and G protein binding characteristics of the seatrout and human
progestin membrane receptor alpha subtypes and their evolutionary
origins. Endocrinology. 148:705–718. 2007. View Article : Google Scholar
|
|
28
|
Pang Y and Thomas P: Progesterone signals
through membrane progesterone receptors (mPRs) in MDA-MB-468 and
mPR-transfected MDA-MB-231 breast cancer cells which lack
full-length and N-terminally truncated isoforms of the nuclear
progesterone receptor. Steroids. 76:921–928. 2011.
|
|
29
|
Krietsch T, Fernandes MS, Kero J, et al:
Human homologs of the putative G protein-coupled membrane progestin
receptors (mPRalpha, beta, and gamma) localize to the endoplasmic
reticulum and are not activated by progesterone. Mol Endocrinol.
20:3146–3164. 2006. View Article : Google Scholar
|
|
30
|
Foster H, Reynolds A, Stenbeck G, Dong J,
Thomas P and Karteris E: Internalisation of membrane progesterone
receptor-alpha after treatment with progesterone: Potential
involvement of a clathrin-dependent pathway. Mol Med Rep. 3:27–35.
2010.
|
|
31
|
Schafer C, Born S, Mohl C, et al: The key
feature for early migratory processes: dependence of adhesion,
actin bundles, force generation and transmission on filopodia. Cell
Adh Migr. 4:215–225. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ishibashi H, Suzuki T, Suzuki S, et al:
Progesterone receptor in non-small cell lung cancer - a potent
prognostic factor and possible target for endocrine therapy. Cancer
Res. 65:6450–6458. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu Y, Hanna RN, Schaaf MJ, Spaink HP and
Thomas P: Candidates for membrane progestin receptors - past
approaches and future challenges. Comp Biochem Physiol C Toxicol
Pharmacol. 148:381–389. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Losel RM, Besong D, Peluso JJ and Wehling
M: Progesterone receptor membrane component 1 - many tasks for a
versatile protein. Steroids. 73:929–934. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guarino M: Src signaling in cancer
invasion. J Cell Physiol. 223:14–26. 2010.
|
|
36
|
Hanke JH, Gardner JP, Dow RL, et al:
Discovery of a novel, potent, and Src family-selective tyrosine
kinase inhibitor. Study of Lck- and FynT-dependent T cell
activation. J Biol Chem. 271:695–701. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Karni R, Mizrachi S, Reiss-Sklan E, Gazit
A, Livnah O and Levitzki A: The pp60c-Src inhibitor PP1 is
non-competitive against ATP. FEBS Lett. 537:47–52. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Finn RS, Bengala C, Ibrahim N, et al:
Dasatinib as a single agent in triple-negative breast cancer:
results of an open-label phase 2 study. Clin Cancer Res.
17:6905–6913. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tryfonopoulos D, Walsh S, Collins DM, et
al: Src: a potential target for the treatment of triple-negative
breast cancer. Ann Oncol. 22:2234–2240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mitra SK, Hanson DA and Schlaepfer DD:
Focal adhesion kinase: in command and control of cell motility. Nat
Rev Mol Cell Biol. 6:56–68. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Owens LV, Xu L, Craven RJ, et al:
Overexpression of the focal adhesion kinase (p125FAK) in invasive
human tumors. Cancer Res. 55:2752–2755. 1995.PubMed/NCBI
|
|
42
|
Siesser PM and Hanks SK: The signaling and
biological implications of FAK overexpression in cancer. Clin
Cancer Res. 12:3233–3237. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hsu SP, Chen TH, Chou YP, et al:
Extra-nuclear activation of progesterone receptor in regulating
arterial smooth muscle cell migration. Atherosclerosis. 217:83–89.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Herbst RS, Yano S, Kuniyasu H, et al:
Differential expression of E-cadherin and type IV collagenase genes
predicts outcome in patients with stage I non-small cell lung
carcinoma. Clin Cancer Res. 6:790–797. 2000.PubMed/NCBI
|
|
45
|
Martinella-Catusse C, Nawrocki B, Gilles
C, Birembaut P and Polette M: Matrix-metalloproteinases in
bronchopulmonary carcinomas. Histol Histopathol. 14:839–843.
1999.PubMed/NCBI
|
|
46
|
Aleshin A and Finn RS: SRC: a century of
science brought to the clinic. Neoplasia. 12:599–607.
2010.PubMed/NCBI
|
|
47
|
Hung WC, Tseng WL, Shiea J and Chang HC:
Skp2 overexpression increases the expression of MMP-2 and MMP-9 and
invasion of lung cancer cells. Cancer Lett. 288:156–161. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xu XM, Zhang Y, Qu D, Feng XW, Chen Y and
Zhao L: Osthole suppresses migration and invasion of A549 human
lung cancer cells through inhibition of matrix metalloproteinase-2
and matrix metallopeptidase-9 in vitro. Mol Med Report.
6:1018–1022. 2012.PubMed/NCBI
|
